Pletal cilostazol: Phase IV data

The double-blind, Japanese Phase IV CSPS 2 trial in 2,757 patients showed that Pletal was non-inferior to aspirin on the primary endpoint of the incidence of stroke (cerebral infarction, cerebral hemo...